TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Transcenta, Biologics, Antibody, Claudin 18.2

TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Careers Contact
English
简体 English 繁体

Latest News

Press Release
2023-10-04
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients
2023-07-31
Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density
2023-07-07
Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001)
More More
Events
2023-08-15
Transcenta to Present Three Study Results at ESMO 2023
2023-06-16
Transcenta to Present Efficacy Data by CLDN18.2 Expression Level from Phase 1/2 Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at 2023 ESMO GI Annual Congress
More More


Innovation

Discovery

Employing a unique antibody generation platform based on Immune Tolerance Breaking Technology to generate therapeutic candidate leads with differentiated biological profile and enhanced druggability attributes.

Translational Research

Our translational research generates PK, PD, Tox and immunogenicity data through validated quantitative platforms, and enables us to model clinical responses to our investigational agents for better understanding of PK/PD/Safety profiles, which guides design and conduct of clinical studies.

Process Development

We can leverage both classical fed-batch and perfusion-based continuous bioprocessing technologies to enable fast-to-IND and fast-to-market process development.

Clinical Development

Based in Beijing, Shanghai, Guangzhou and Princeton, US, our teams at global clinical development centers and regulatory teams have extensive knowledge and experience in designing and executing clinical trials at all stages.

Manufacturing

Equipped with a flexible modular manufacturing facility and advanced next-generation perfusion bioprocessing platform, we are able to significantly accelerate process development and reduce the cost of manufacturing.

Partnering

Benefited from the global network and industry resources of our prominent shareholders with deep biotech expertise, we have forged multiple forms of important strategic cooperation with leading domestic and international pharmaceutical companies and equipment suppliers.

2012
Company Established
139
Issued & Pending Patents
13
Pipeline
2021
Listed in HKEX
6
Global Footprints